Estrogen and progesterone receptors have important role in management of breast cancer. Our study aim to evaluate the effect of radiotherapy with different estrogen and progesterone receptors status.
SEER database used to obtain patient data. All 18 SEER registries were used to estimate five-year relative survival rates of non-metastatic breast cancer cases with negative lymph node infiltration patient who received radiotherapy (RT) between 1998 and 2007 by Kaplan-Meir method. We compared relative survival rates among groups of patients categorized by estrogen and progesterone receptors status.
200535 patient who met selection criteria in SEER database was divided into 9 groups depending on estrogen (ER) and progesterone (PR) receptor status ]positive (+), negative (-) or borderline (b)[. The result showed that there was significant difference in five-years relative survival rate in patient who received RT comparing with patient who didn't receive RT in ER+ & PR+ ]100% & 98.5% (95% CI:98.1-98.8) respectively[ (P value >0.001), ER+ & PR- ]100% & 95.1% (95% CI:94.2-95.8) respectively[ (P value >0.001), ER- & PR+ ]97.6% (95% CI:95.6-98.7) & 92% (95% CI:89.7-93.8) respectively[ (P value >0.001), ER- & PR- ]93.8% (95% CI:93.3-94.2) & 91.5% (95% CI:87.5-88.7) respectively[ (P value >0.001), ERb & PR- ]97.5% (95% CI:79.5-99.7) & 90.4% (95% CI:78.8-95.8) respectively[ (P value =0.028) & ERb & PRb ]98.5% (95% CI:31.6-100) & 84% (95% CI:73.2-90.7) respectively[ (P value =0.003) groups. The study showed that ER+ status has 100% five years relative survival rate with all PR receptor status.
RT is highly recommended in patient with ER+ regardless the status of PR receptor status. Also it is recommended in previous sub group which showed significant difference between patients who received RT comparing with patients who didn't receive RT.
Clinical trial identification
Legal entity responsible for the study
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute
All authors have declared no conflicts of interest.